COLOPLAST A/S

Coloplast A/S discloses major shareholdings through statutory flagging notifications to Nasdaq Copenhagen and the Danish Financial Supervisory Authority. As of the most recent major-shareholder notification, dated 18 August 2023, the largest disclosed shareholder is Coloplast Holding ApS, which held 30.75% of the share capital and 52.79% of the voting rights in Coloplast A/S. Coloplast Holding ApS is in turn controlled by two holding vehicles associated with the founding Louis-Hansen family: NPLH Holding ApS, which held 62.58% of the share capital and 71.13% of the voting rights in Coloplast Holding ApS, and Aage og Johanne Louis-Hansen A/S, which held the remaining 37.42% of the share capital and 28.87% of the voting rights in Coloplast Holding ApS. Aage og Johanne Louis-Hansen A/S is wholly owned by the charitable foundation Aage og Johanne Louis-Hansens Fond. Because Coloplast A/S is listed on Nasdaq Copenhagen, public disclosure covers only holdings that cross statutory flagging thresholds; the complete shareholder register is not publicly published.

### Ultimate beneficial ownership

Niels Peter Louis-Hansen, son of Coloplast co-founder Aage Louis-Hansen, is reported to hold, directly and indirectly through the NPLH Holding ApS and Coloplast Holding ApS structure, 32.76% of the share capital and 56.54% of the voting rights in Coloplast A/S, as calculated from the 18 August 2023 notification chain. This is a calculated effective interest based on the disclosed ownership chain rather than a single filed percentage. No other individual meeting a comparable disclosure threshold has been identified from official notifications reviewed.

### Data availability

Shareholder disclosure for Coloplast A/S is major shareholders only: Danish and EU flagging rules require public disclosure only once a holding crosses set thresholds, so shareholdings below the reporting threshold are not publicly visible. The percentages above reflect the ownership chain notified on 18 August 2023; no more recent major-shareholder notification revising these figures was identified in the sources reviewed.

### Sources

– Coloplast A/S, “Largest shareholder and Foundation to secure Coloplast future with new holding company,” official press release, coloplast.com, 18 August 2023, retrieved 15 September 2026.
– “Major shareholder notification,” Coloplast A/S via GlobeNewswire, 18 August 2023 (mirrored by Yahoo Finance and StreetInsider), retrieved 15 September 2026.
– Danish Business Authority, Central Business Register (CVR), entity CVR 69749917, used for entity verification, retrieved 15 September 2026.

The Danish CVR-sourced officer extract available for this profile lists 96 historical board appointments dating back to 1957, the great majority marked as resigned, and does not include current, active appointment records. Current leadership below is therefore based on Coloplast A/S’s own official announcements. Effective 1 May 2026, Gavin Wood was appointed President and Chief Executive Officer of the Coloplast Group, succeeding Lars Rasmussen, who had served as interim CEO from 5 May 2025 and subsequently stepped down from the Board of Directors at the Annual General Meeting held on 4 December 2025. Anders Lonning-Skovgaard has served as Executive Vice President and Chief Financial Officer since 2014, with responsibility for Finance, IT, Legal and Investor Relations. Jette Nygaard-Andersen, a Board member since December 2015, was confirmed as Chairman of the Board at the 4 December 2025 Annual General Meeting, having served as interim Chair since 5 May 2025. At the same meeting, Niels B. Christiansen was elected as a new Board member; the company has indicated he is expected to assume the Chairmanship no later than the Annual General Meeting in December 2026.

### Recent officer changes

– Gavin Wood appointed President and CEO, effective 1 May 2026 (Coloplast A/S press release / GlobeNewswire, 4 March 2026).
– Lars Rasmussen stepped down from the Board of Directors at the Annual General Meeting on 4 December 2025, having served as interim CEO from 5 May 2025 (Coloplast A/S press release / GlobeNewswire, 9 October 2025).
– Jette Nygaard-Andersen confirmed as Chairman of the Board at the Annual General Meeting on 4 December 2025, ending an interim chairmanship that began 5 May 2025 (Coloplast A/S Annual General Meeting announcements, December 2025).

### Data availability

Officer and director information for Danish companies is published by the Danish Business Authority (CVR) and is, in principle, full for currently registered directors. However, the CVR extract available to Zavia.ai for this profile contains only historical, resigned appointments and could not be used to confirm the presently active Board composition. Nationality and country of residence for current officers were not confirmed from official sources and are not stated here.

### Sources

– Coloplast A/S, “Coloplast appoints Gavin Wood as new CEO,” official press release, coloplast.com / GlobeNewswire, 4 March 2026, retrieved 15 September 2026.
– Coloplast A/S, “Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting,” GlobeNewswire, 9 October 2025, retrieved 15 September 2026.
– MarketScreener, “Coloplast elects Jette Nygaard-Andersen as chairman,” retrieved 15 September 2026.
– Coloplast A/S, Annual General Meeting minutes 2025, coloplast.com, retrieved 15 September 2026.

Coloplast A/S is the ultimate parent and top consolidating company of the Coloplast Group, publishing the group’s consolidated annual and interim financial statements. Coloplast A/S is itself majority-controlled by Coloplast Holding ApS, a holding company associated with the founding Louis-Hansen family (see the Shareholders section); this is a shareholding relationship rather than a corporate parent-subsidiary relationship, since Coloplast A/S remains the top entity for group financial consolidation. Two verified recent additions to the group are Atos Medical AB (Sweden), a manufacturer of voice and respiratory care products, and Kerecis LLC (United States/Iceland), a producer of fish-skin-derived wound care products, both acquired via confirmed company transactions. The Coloplast Group also operates numerous national sales and manufacturing entities internationally, though a complete, individually sourced list of all direct and indirect subsidiaries with ownership percentages was not available from the sources reviewed.

### Verified corporate relationships

| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|—|—|—|—|—:|—|—|
| Atos Medical AB | Sweden | SE 5562687607 | Subsidiary (acquired) | Ownership percentage not disclosed | Active | 15 September 2026 |
| Kerecis LLC | United States | US VA 5935834 | Subsidiary (acquired) | Ownership percentage not disclosed | Active | 15 September 2026 |

### Recent structural changes

– Coloplast completed the acquisition of Kerecis LLC on 31 August 2023 (Coloplast A/S / GlobeNewswire, 31 August 2023).
– Coloplast completed the acquisition of Atos Medical AB on 31 January 2022, for approximately EUR 2,155 million, described by the company as its largest acquisition to date (Coloplast A/S / GlobeNewswire, 31 January 2022).

### Data availability

Corporate-linkage information for Coloplast A/S is partial: the group’s two largest recent acquisitions are verified through the company’s own transaction announcements, but a complete, sourced list of all direct and indirect subsidiaries with ownership percentages was not available from the sources reviewed. Coloplast A/S is publicly confirmed as the ultimate parent and consolidating entity for Coloplast Group financial reporting.

### Sources

– Coloplast A/S, “Coloplast completes the acquisition of Kerecis,” GlobeNewswire, 31 August 2023, retrieved 15 September 2026.
– Coloplast A/S, “Coloplast A/S – Coloplast completes the acquisition of Atos Medical,” GlobeNewswire, 31 January 2022, retrieved 15 September 2026.
– Coloplast A/S, “Coloplast A/S – Announcement no. 09/2021 – Coloplast announces agreement to acquire Atos Medical,” GlobeNewswire, 8 November 2021, retrieved 15 September 2026.